Pharma major Lupin announced the launch of Clobetasol Propionate Ointment USP 0.05%, having received an approval from the United States Food and Drug Administration (FDA) earlier.

Lupin's Clobetasol Propionate Ointment USP, 0.05% is the generic equivalent of Fougera Pharmaceuticals Inc.'s Temovate Ointment, 0.05%. It is a super-high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Clobetasol Propionate Ointment USP 0.05% had annual sales of approximately USD 93.4 million in the US (IQVIA MAT June 2018).

Shares of the company gained Rs 13.7, or 1.58%, to trade at Rs 879.20. The total volume of shares traded was 23,154 at the BSE (9.49 a.m., Wednesday).